FindTrial
Sign In

Abrocitinib 100 mg

DRUG3 trials

Sponsors

Pfizer, Innovaderm Research Inc.

Conditions

Atopic DermatitisChronic Hand EczemaDermatitis, Atopic

Phase 2

Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy
CompletedNCT06283550
Innovaderm Research Inc.Chronic Hand Eczema
Start: 2024-05-31End: 2025-11-03Updated: 2026-02-03

Phase 3

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
CompletedNCT03422822
PfizerDermatitis, Atopic
Start: 2018-03-08End: 2025-12-22Updated: 2026-01-15
A Study to Learn About Abrocitinib Tablets in People With Atopic Dermatitis in India
CompletedNCT05375929
PfizerAtopic Dermatitis
Start: 2022-07-16End: 2024-03-14Updated: 2024-10-15

Related Papers

Efficacy and Safety of Variable-Dose Versus Continuous-Dose Abrocitinib Treatment in Patients with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis.
2026-05-20
Long-term efficacy of abrocitinib in patients with moderate-to-severe atopic dermatitis to 2 years.
2026-04-28
Durability of Response After Pausing Abrocitinib Treatment in Patients With Moderate-to-Severe Atopic Dermatitis
SKIN The Journal of Cutaneous Medicine2025-11-10
Integrated Safety Analysis of Abrocitinib in 3850 Patients With Moderate-To-Severe Atopic Dermatitis: Data From More Than 9600 Patient-Years With Up to 6.5 Years of Exposure
SKIN The Journal of Cutaneous Medicine2025-11-10
Patients With Moderate-to-Severe Atopic Dermatitis Maintained Depth of Response Up to 2 Years With Continuous Abrocitinib Treatment
SKIN The Journal of Cutaneous Medicine2025-11-10
Integrated Efficacy and Safety Analysis of Abrocitinib in Adolescents With Moderate‐to‐Severe Atopic Dermatitis
Allergy2025-03-033 citations
Switching from Dupilumab to Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Efficacy After Treatment With Dupilumab in JADE DARE
Dermatology and Therapy2025-02-014 citations
Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of Exposure
American Journal of Clinical Dermatology2024-06-1834 citations
Abrocitinib May Improve Itch and Quality of Life in Patients with Itch-Dominant Atopic Dermatitis
Skin Health and Disease2024-05-052 citations
Integrated Safety Analysis of Abrocitinib in 635 Adolescent Patients With Moderate-To-Severe Atopic Dermatitis With Over 1000 Patient-Years of Exposure
SKIN The Journal of Cutaneous Medicine2024-03-18
530 - Treatment efficacy in patients with moderate-to-severe atopic dermatitis who switched from dupilumab to abrocitinib in JADE EXTEND, a phase 3 long-term extension study
British Journal of Dermatology2024-02-01
Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice.
2023-07-233 citations
Effect of abrocitinib and dupilumab on eosinophil levels in patients with moderate‐to‐severe atopic dermatitis
JEADV Clinical Practice2023-06-231 citations
Abrocitinib efficacy and safety in patients with moderate‐to‐severe atopic dermatitis: Results from phase 3 studies, including the long‐term extension JADE EXTEND study
Journal of the European Academy of Dermatology and Venereology2023-06-1932 citations
Abrocitinib effect on patient‐reported outcomes in patients with moderate‐to‐severe atopic dermatitis: Results from phase 3 studies, including the long‐term extension <scp>JADE EXTEND</scp> study
Journal of the European Academy of Dermatology and Venereology2023-06-156 citations
P81 Long-term efficacy of abrocitinib in adolescents and adults with moderate-to-severe atopic dermatitis: a post hoc analysis of JADE EXTEND
British Journal of Dermatology2023-06-012 citations
383 Integrated safety analysis of abrocitinib in 635 adolescent patients with moderate-to-severe atopic dermatitis with over 1000 patient-years of exposure
British Journal of Dermatology2023-06-011 citations
423 Long-term efficacy of abrocitinib up to 96 weeks in adults with moderate-to-severe atopic dermatitis stratified by age: a post hoc analysis of the JADE EXTEND phase 3 trial
British Journal of Dermatology2023-06-01
Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial
American Journal of Clinical Dermatology2023-05-2221 citations
Short-Term Efficacy and Safety of Abrocitinib by Baseline Disease Severity in Patients With Moderate-to-Severe Atopic Dermatitis
SKIN The Journal of Cutaneous Medicine2023-03-13

3 more papers not shown